Commonly Prescribed Glaucoma Drug May Be Effective In Treating Male Pattern Baldness And Other Forms Of Alopecia

If you’re balding and want your hair to grow back, then here is some good news. A new research report appearing online in The FASEB Journal shows how the FDA-approved glaucoma drug, bimatoprost, causes human hair to regrow. It’s been commercially available as a way to lengthen eyelashes, but these data are the first to show that it can actually grow human hair from the scalp.

 

Eyedrop for Treatment of Cataract under study

Experimental eyedrop, prepared with the antioxidant N-acetylcysteine amide (NACA), have been used as treatment for the prevention or healing of cataracts, macular degeneration, and other degenerative eye disorders. Studies showed that the NACA solution prevented cataracts from forming and will now be tested further to see if degeneration reversal is possible.

Lumigan, Latisse Drug Class and Mechanism

GENERIC NAME: bimatoprost

BRAND NAME: Latisse, Lumigan

DRUG CLASS AND MECHANISM: Bimatoprost is a synthetic (man-made) drug that resembles and mimics the effects of natural chemicals (prostaglandins) produced by the body. It is used for reducing intraocular pressure (IOP) and increasing the growth of eyelashes. The exact mechanism of action is unknown. Bimatoprost may reduce IOP by increasing the outflow of aqueous humor from the eye of individuals with narrow angle glaucoma. Excessive aqueous humor may cause optic nerve damage and visual loss. It may increase eyelash growth by increasing the duration of the growing phase of the eyelash. The FDA approved Lumigan in March 2001 and Latisse in December 2008.

FDA Approves Eylea For Wet Macular Degeneration

The U.S. Food and Drug Administration approved Eylea (aflibercept) to treat patients with wet (neovascular) age-related macular degeneration (AMD), a leading cause of vision loss and blindness in Americans ages 60 and older.
Other FDA-approved treatment options for wet AMD include: Visudyne (verteporfin for injection) approved in 2000, Macugen (pegaptanib sodium injection) approved in 2004, and Lucentis (ranibizumab injection) approved in 2006.
Studies showed that Eylea was as effective as Lucentis in maintaining or improving visual acuity.